Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

被引：11
|
作者：
Tamburini, J. [1 ]
Elie, C. [2 ]
Park, S. [1 ]
Beyne-Rauzy, O. [3 ]
Gardembas, M. [4 ]
Berthou, C. [5 ]
Mahe, B. [6 ]
Sanhes, L. [7 ]
Stamatoullas, A. [8 ]
Vey, N. [9 ]
Aouba, A.
Slama, B. [10 ]
Quesnel, B. [11 ]
Vekhoff, A. [13 ]
Sotto, J. J. [12 ]
Vassilief, D. [1 ]
Al-Nawakil, C. [1 ]
Fenaux, P. [14 ]
Dreyfus, F. [1 ]
Bouscary, D. [1 ]
机构：
[1] Hop Cochin, Dept Haematol, Paris, France
[2] Univ Paris 05, Dept Biostat, F-75270 Paris 06, France
[3] Hop Purpan, Dept Hematol Odile, Toulouse, France
[4] Ctr Hosp Angers, Dept Hematol Martine, Angers, France
[5] Hop Brest, Dept Hematol Christian, Brest, France
[6] Ctr Hosp Nantes, Dept Hematol, Nantes, France
[7] Ctr Hosp Perpignan, Dept Hematol, Perpignan, France
[8] Ctr Hosp Rouen, Dept Hematol Aspasia, Rouen, France
[9] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[10] Ctr Hosp Avignon, Dept Hematol, Avignon, France
[11] Ctr Hosp Lille, Dept Hematol, Lille, France
[12] Ctr Hosp Grenoble, Dept Hematol, Grenoble, France
[13] Hop Hotel Dieu, Dept Hematol, F-75181 Paris, France
[14] Hop Avicenne, Dept Hematol, Bobigny, France
来源：
LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期
关键词：
INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; ANEMIA; PROPOSAL;
D O I：
10.1016/j.leukres.2008.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：547 / 550
页数：4
相关论文
共 50 条
  • [31] The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome
    Cordoba, I.
    Gonzalez-Porras, J. R.
    Such, E.
    Nomdedeu, B.
    Luno, E.
    de Paz, R.
    Carbonell, F.
    Vallespi, T.
    Ardanaz, M.
    Ramos, F.
    Marco, V.
    Bonanad, S.
    Sanchez-Barba, M.
    Costa, D.
    Bernal, T.
    Sanz, G. F.
    Canizo, M. C.
    LEUKEMIA RESEARCH, 2012, 36 (03) : 287 - 292
  • [32] Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes A Randomized Trial
    Angelucci, Emanuele
    Li, Junmin
    Greenberg, Peter
    Wu, Depei
    Hou, Ming
    Montano Figueroa, Efreen Horacio
    Guadalupe Rodriguez, Maria
    Dong, Xunwei
    Ghosh, Jagannath
    Izquierdo, Miguel
    Garcia-Manero, Guillermo
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (08) : 513 - +
  • [33] Treatment of anemia in low risk myelodysplastic syndromes with granulocyte–macrophage colony-stimulating factor plus recombinant human erythropoietin
    T Economopoulos
    S Mellou
    E Papageorgiou
    V Pappa
    V Kokkinou
    E Stathopoulou
    M Pappa
    S Raptis
    Leukemia, 1999, 13 : 1009 - 1012
  • [34] A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mufti, Ghulam
    Mittelman, Moshe
    Muus, Petra
    Boekhorst, Peter Te
    Sanz, Guillermo
    del Canizo, Consuelo
    Guerci-Bresler, Agnes
    Nilsson, Lars
    Platzbecker, Uwe
    Luebbert, Michael
    Quesnel, Bruno
    Cazzola, Mario
    Ganser, Arnold
    Bowen, David
    Schlegelberger, Brigitte
    Aul, Carlo
    Knight, Robert
    Francis, John
    Fu, Tommy
    Hellstrom-Lindberg, Eva
    BLOOD, 2011, 118 (14) : 3765 - 3776
  • [35] Erythropoiesis stimulating agents and other growth factors in low-risk MDS
    Hellstrom-Lindberg, Eva p
    van de Loosdrecht, Arjan
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2013, 26 (04) : 401 - 410
  • [36] The Clinical Efficacy of Chelation Therapy in Patients with Myelodysplastic Syndrome, Low Risk
    Yunusova, Zulkhumor Djumabaevna
    Saydamanova, Sayora
    Babadzhanova, Shahida
    Akhanov, Khiril
    Gritsaev, Sergey Vasilyevich
    Kostroma, Ivan Ivanovich
    Zhernakova, Anastasia
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S338 - S339
  • [37] Predictors of ISUP score upgrade in patients with low-risk prostate cancer
    Haberal, Hakan Bahadir
    Artykov, Meylis
    Hazir, Berk
    Citamak, Burak
    Altan, Mesut
    Yazici, Sertac
    Akdogan, Bulent
    Ozen, Haluk
    TUMORI JOURNAL, 2021, 107 (03): : 254 - 260
  • [38] Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study
    Balleari, E
    Rossi, E
    Clavio, M
    Congiu, A
    Gobbi, M
    Grosso, M
    Secondo, V
    Spriano, M
    Timitilli, S
    Ghio, R
    ANNALS OF HEMATOLOGY, 2006, 85 (03) : 174 - 180
  • [39] Successful treatment of low-risk myelodysplastic syndrome-related anemia in patients with chronic kidney disease with daprodustat: A report of two cases
    Kunimoto, Hiroyoshi
    Sakuma, Takayuki
    Ohashi, Takuma
    Shirafuta, Mayoko
    Teranaka, Hiroshi
    Nakajima, Hideaki
    EJHAEM, 2024,
  • [40] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Hellmann, Andrzej
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Pollyea, Daniel A.
    DesJardins, Pierre
    Ottmann, Oliver
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Laird, A. Douglas
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    LEUKEMIA, 2019, 33 (02) : 379 - 389
12345